

4DMedical progresses towards full reimbursement in the U.S.

19 October 2022

Highlights

- American Medical Association accepts XV LVAS® application to establish a new CPT code.
- Category III CPT code is a critical milestone for XV LVAS® to become a fully commercialised and reimbursable product in the U.S..
- Cat III codes enable the assessment, and can establish the payment of, new services and procedures.
- Expands 4DMedical's product visibility in the broader U.S. payer space.

Melbourne, Australia, 19 October 2022: Respiratory imaging technology company 4DMedical Limited (ASX:4DX, '4DMedical', or the 'Company') today announces that the American Medical Association ('AMA') Current Procedural Terminology ('CPT') Editorial Panel has accepted 4DMedical's application for the addition of a new Category III CPT code ('Cat III code') to identify the use of their XV Lung Ventilation Analysis Software ('XV LVAS®') technology distinctly.

In September 2022, the AMA CPT Editorial Panel convened in Seattle, WA, to review applications for modifications to the AMA CPT code sets. 4DMedical applied to establish a new, distinct, Category III CPT code (Pulmonary Tissue Ventilation Analysis) to identify the use of their XV LVAS® technology amongst healthcare providers and payers. Released October 14, 2022, the *CPT Editorial Summary of Panel Actions September 2022* confirmed the acceptance of 4DMedical's application for the new Category III CPT code. The specific Category III CPT code and code descriptor will be released on January 1, 2023 and be effective for use on July 1, 2023.

CPT codes represent a national, standardised system that U.S. healthcare providers use to report medical services and procedures under public and private health insurance programs. CPT codes enable streamlined reporting and increased accuracy and efficiency in the healthcare claims process. The CPT Editorial Panel, appointed by the AMA Board of Trustees, is an independent group of expert volunteers representing various sectors of the healthcare industry and is responsible for maintaining and updating the CPT code set.

AMA Category III CPT codes are a set of temporary codes for new and emerging technologies created for data collection to substantiate the widespread usage of the technology. Cat III codes enable the assessment, and can establish the payment of, new services and procedures.

Creating a distinct Category III CPT code for 4DMedical's XV LVAS® technology is a critical step towards commercial success in the U.S.. The new Cat III code will allow healthcare providers to identify when a patient has received an XV LVAS® scan, provide a billing pathway amongst payers, and enable tracking utilisation of the technology. Additionally, a distinct Category III CPT code opens the door for early engagements with payers to introduce XV LVAS® technology while also enabling discussions to establish reimbursement as 4DMedical continues to advance its US commercialisation rollout demonstrating the positive real-world clinical outcomes and economic value of the technology.



–ENDS–

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

CFO

Simon Glover

sglover@4dmedical.com

Administration

Company Secretary

Melanie Leydin

companysecretary@4dmedical.com

Media Enquiries

TCN

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company that has created a step change in the capacity to accurately and quickly understand the lung function of patients with respiratory diseases.

Through its flagship patented XV Technology[®], 4DMedical enables physicians to understand regional airflow in the lungs and identify respiratory deficiencies earlier and with greater sensitivity as they breathe. This technology powers 4DMedical's FDA-cleared XV Lung Ventilation Analysis Software (XV LVAS[®]), the first and only modality to dynamically quantify ventilation throughout the lungs. It also exposes the patient to lower radiation levels relative to other diagnostic methods, a clear advantage when disease progression and therapeutic effectiveness need to be regularly monitored.

XV LVAS[®] reports are prepared using 4DMedical's Software as a Service delivery model using existing hospital imaging equipment or the Company's revolutionary XV Scanner.

To learn more, please visit www.4dmedical.com.